-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-504888-16-00
9
2020-10-05
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-514383-61-00
6
2020-07-07
Diarrhoea predominant irritable bowel syndrome
-
2024-510841-32-00
1
2020-05-27
Advanced or metastatic carcinomas after previous immune checkpoint blo
-
2024-514494-21-00
4
2020-05-13
autoimmune encephalitis
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-512104-19-00
6
2019-11-19
Irritable Bowel Syndrome
-
2024-510964-21-00
9
2019-09-12
Glioblastoma
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2025-523974-18-00
5
2026-04-30
Obesity
-
2024-516994-59-00
4
2026-02-13
Bronchopulmonary Dysplasia
-
2024-517413-33-00
4
2026-02-03
Idiopathic Parkinson's Disease
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)
-
2024-513008-32-00
4
2025-12-17
Adenocarcinoma of the gastroesophageal junction
-
2024-517091-38-00
3
2025-11-25
Head and neck squamous cell carcinoma
-
2024-519469-23-00
4
2025-10-20
Severe Asthma